Roth Capital set a $3.00 price objective on BioLineRx Ltd. (NASDAQ:BLRX) in a report released on Wednesday. The firm currently has a buy rating on the biotechnology company’s stock.

Several other equities research analysts have also recently weighed in on BLRX. HC Wainwright set a $4.00 target price on BioLineRx and gave the stock a buy rating in a report on Tuesday, April 18th. Zacks Investment Research upgraded BioLineRx from a hold rating to a buy rating and set a $1.00 target price for the company in a report on Friday, April 21st. Maxim Group upgraded BioLineRx from a hold rating to a buy rating and upped their target price for the stock from $1.00 to $3.00 in a report on Thursday, May 18th. Finally, ValuEngine upgraded BioLineRx from a sell rating to a hold rating in a report on Monday, July 17th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. BioLineRx presently has an average rating of Buy and an average price target of $2.59.

BioLineRx (NASDAQ:BLRX) traded up 2.63% during trading on Wednesday, reaching $1.17. The company’s stock had a trading volume of 439,418 shares. BioLineRx has a 12-month low of $0.80 and a 12-month high of $1.42. The firm’s 50-day moving average price is $0.96 and its 200 day moving average price is $0.97. The company’s market capitalization is $111.87 million.

BioLineRx (NASDAQ:BLRX) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). On average, analysts predict that BioLineRx will post ($0.24) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Roth Capital Analysts Give BioLineRx Ltd. (NASDAQ:BLRX) a $3.00 Price Target” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://theolympiareport.com/2017/08/12/roth-capital-analysts-give-biolinerx-ltd-nasdaqblrx-a-3-00-price-target.html.

Several large investors have recently modified their holdings of BLRX. Citadel Advisors LLC boosted its stake in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after buying an additional 86,481 shares during the period. Renaissance Technologies LLC bought a new stake in shares of BioLineRx during the first quarter worth $126,000. Benchmark Capital Advisors boosted its stake in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after buying an additional 100,000 shares during the period. KCG Holdings Inc. boosted its stake in shares of BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after buying an additional 153,687 shares during the period. Finally, Sabby Management LLC bought a new stake in shares of BioLineRx during the first quarter worth $3,018,000. Hedge funds and other institutional investors own 34.91% of the company’s stock.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.